ScholarIQanswers from OpenAlex & ORCID
Gunnar B. Kristensen
ResearcherPublications, citations & collaboration network
Gunnar B. Kristensen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Gunnar B. Kristensen have?
ScholarIQindexed works
Gunnar B. Kristensen has 429 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Gunnar B. Kristensen have?
ScholarIQcitation count
Gunnar B. Kristensen has 25,253 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Gunnar B. Kristensen?
ScholarIQh-index
Gunnar B. Kristensen has an h-index of 71 in OpenAlex.
What is the i10-index of Gunnar B. Kristensen?
ScholarIQi10-index
Gunnar B. Kristensen has an i10-index of 225 in OpenAlex.
What is the ORCID of Gunnar B. Kristensen?
ScholarIQorcid
The ORCID for Gunnar B. Kristensen is on the source record.
What is the OpenAlex record for Gunnar B. Kristensen?
ScholarIQopenalex
The OpenAlex for Gunnar B. Kristensen is on the source record.
What are the most-cited papers on Gunnar B. Kristensen?
ScholarIQmost cited works
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote, Claes G. Tropé, Frédéric Amant, Gunnar B. Kristensen, Tom Ehlen, Nick Johnson, René H.M. Verheijen, Maria E.L. van der Burg, Ángel J. Lacave, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Corneel Coens, Leen Verleye, Gavin Stuart, Sërgio Pecorelli, N.S. Reed
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A. Ledermann, Éric Pujade-Lauraine, Gunnar B. Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédèric Selle, Mansoor R. Mirza, Arto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh Parmar, Amit M. Oza
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Éric Pujade-Lauraine, Felix Hilpert, B. Weber, Alexander Reuß, Andrés Poveda, Gunnar B. Kristensen, Roberto Sorio, Ignace Vergote, Petronella O. Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Mansoor Raza Mirza, Philippe Follana, David T. Bollag, Isabelle Ray‐Coquard
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Mahesh Parmar, Jonathan A. Ledermann, Nicoletta Colombo, Andreas du Bois, Delaloye Jf, Gunnar B. Kristensen, Sarah Wheeler, Ann Marie Swart, W. Qian, Valter Torri, Irene Floriani, Gordon C. Jayson, Alan Lamont, C. Tropé
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Amit M. Oza, Adrian Cook, Jacobus Pfisterer, Andrew Embleton-Thirsk, Jonathan A. Ledermann, Éric Pujade-Lauraine, Gunnar B. Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Tjoung‐Won Park‐Simon, Gordon Rustin, Florence Joly, Mansoor Raza Mirza, Marie Plante, Michael Quinn, Andrés Poveda, Gordon C. Jayson, Dan Stark, Ann Marie Swart, Laura Farrelly, Richard Kaplan, Mahesh Parmar, Timothy Perren